Company's Canalevia®-CA1 prescription drug is FDA conditionally approved for treatment of chemotherapy-induced diarrhea (CID) in dogs and is the first and only treatment for CID in dogs to receive any type of approval from FDA
Read MoreModerna's updated COVID-19 mRNA vaccine will be available for the 2024-2025 vaccination season, pending a European Commission authorization decision
Read MoreDomitner GmbH placed initial order that is expected to ship in the third quarter of 2024
Combined with the German distribution announced in July, there is strong coverage in central Europe
Additional European distributors are expected to be secured in 2024
MODD1 is a patch pump for ALL adults with Type 1 and Type 2 diabetes
Designed to be simpler and more affordable to expand access to diabetes technology for previously underserved communities
Commercial availability expected in early 2025
Click here to view interview video
Paramount near-term activities include planned October 2024 commercial launch of FDA-approved oral mucositis prescription product Gelclair® and results from independent, investigator-initiated trials of crofelemer for rare diseases
Read More
Approval follows recommendation from global public health bodies to develop JN.1 COVID-19 vaccines
At present, the JN.1 group of subvariants remain dominant in the UK
The updated vaccine will be available for eligible groups as part of the NHS autumn vaccination program, and will also be available to purchase privately in the UK for the first time
Read More
New campaign aims to inform and educate the public about the ongoing risks of COVID-19 and the impact the virus continues to have on day-to-day life
Updated vaccines targeting KP.2 variant have been approved by the U.S. FDA and are now available across the country
Read MoreMMJ International Holdings has submitted to the FDA for approval of its soft gelatin capsule to be used in clinical trails for its Huntington Disease Study. MMJ has received an Orphan designation from the FDA. Once FDA approved the company will be one of a very few with federal authorization to sell its medication.
Read More
New patent issued for core rare disease target indication for crofelemer
Napo has approximately 230 patents issued and pending
Jaguar is supporting independent investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of SBS and microvillus inclusion disease (MVID), an ultrarare congenital diarrheal disorder (CDD), in the US, EU, and Middle East/North Africa regions, with results expected by the end of 2024 and throughout 2025
Read More
